Group 4E: HER2+ Breast Cancer; Triple Positive Breast Cancer; Clinical Trials; Treatment Resistance

Name: Group 4E: HER2+ Breast Cancer; Triple Positive Breast Cancer; Clinical Trials; Treatment Resistance
Start: 2023-12-15
End: 2023-12-15

Poster #PS09-08: Genomic characterization of endocrine resistance in ER+HER2+ breast cancers in the POETIC Trial.

Poster #PS03-04: Tumor immune microenvironment modulates resistance to estrogen suppression in ER+ breast cancer.